4 research outputs found
This is the existence of Allah according to Ismail Fenni Ertugrul
No full textYüksek Lisans Tezi"İsmail Fenni Ertuğrul’a Göre Allah’ın Varlığı" adını taşıyan bu araştırmamız
üç bölümden oluşmaktadır. Her dönemde kelamcılar felsefi ve mantıki argümanlar
geliştirerek nesillere Yüce Allah’ın varlığını kavramada kolaylaştırıcı çalışmalar
yapmışlardır. Doğrudan kelamcı olmasa da Kelam ilminin temel konularından biri
olan Allah’ın varlığını ispat konusunda değerli araştırmalar yapan şahsiyetlerden
birisi de İsmail Fenni Ertuğrul’dur. Materyalist ve Pozitivist akımlara karşı
yönelttiği ciddi tenkitleri ve Allah’ın varlığı konusunda ortaya koyduğu çeşitli
görüşleri vardır.
Birinci bölümde, İsmail Fenni Ertuğrul’un hayatı, eserleri ve ilmi kişiliğini ele
aldık. Ayrıca Osmanlıdaki batı tesirindeki gelişmelerin ve kökeni Batı’ya dayanan,
ülkemizde de temsilcileri bulunan materyalist fikir akımlarına değindik.
İkinci bölümde ise, İslam Kelam’ında ve Felsefede geliştirilen isbat-ı vacip
delillerini mukayeseli bir biçimde ele alarak Allah’ın varlığını isbata çalıştık.
Üçüncü bölümde de, bazı batılı filozof ve ilim adamlarının Tanrı anlayışlarıyla
ilgili görüşlerine karşı İsmail Fenni Ertuğrul’un yaklaşımlarını kendi bakış açısıyla
tahlil ettik. İsmail Fenni, gaiyye delilini kullanmak suretiyle materyalistlerin ve
Pozitivistlerin bakış açılarına ciddi eleştiriler getirmiştir."This is the existence of Allah according to Ismail Fenni Ertugrul" is composed of
three parts. In every period, theologians developed philosophical and logical
arguments and made efforts to help generations to grasp the existence of Almighty
God. Ismail Fenni Ertugrul is one of the personalities who make valuable researches
to prove the existence of God, which is one of the basic subjects of theology, although
it is not a direct author. He has serious criticisms of the materialist and positivist
movements, and he has various views on the existence of God.
In the first chapter, we discussed the life, works and scientific personality of
İsmail Fenni Ertuğrul. In addition, we have touched on the developments in the
Ottoman influence in the Ottoman Empire and the materialist ideological ideals that
are based on the West and have representatives in our country.
In the second chapter, we tried to examine the existence of God in a comparative
way by examining the proofs of isbat-ı vacip developed in the Islamic Philosophy and
Philosophy.
In the third chapter, we analyzed the approaches of philosopher İsmail Fenni
Ertuğrul to the point of view of some Western philosophers and scholars about their
understanding of God. Ismail Fenni, using the evidence of the gaiyya, brought serious
criticism to the perspectives of materialists and positivists
Relations among Pain, Pain Beliefs, and Psychological Well-Being in Patients with Chronic Pain
No full textTopcu, Sacide Yildizeli (Trakya author)Background: Chronic pain influencing the quality of life and well-being of the patients are also affected by pain beliefs. Psychological well-being could make a person have positive pain beliefs and these could facilitate patients' coping skills. In the care of the patients with chronic pain, nursing interventions can improve patients' well-being. Aims: This study aimed to determine the relationship between pain, pain beliefs and psychological well-being in patients with chronic pain. Design: A cross-sectional and relational study. Subjects: This study was conducted with 86 patients with chronic joint pain. Methods: A convenience sample method was used in the research. Data were gathered using a Personel Information Form, The Pain Beliefs Questionnaire and Psychological Well-being Scale. Frequency, percentage, mean, standard deviation and correlation analysis were used for data assessment. Results: It was found that there was a statistically significant correlation between pain severity and organic pain beliefs, statistically significant negative correlation between frequency and severity of pain and psychological well-being, and statistically significant relationship between organic pain beliefs and the psychological wellbeing. Conclusions: Organic pain beliefs and pain intensity affect the psychological well-being of the patients with chronic pain. To increase the psychological well-being level of patients with chronic pain, patients' informations, attitudes and beliefs about pain and pain control should be changed positively. Also, nursing care focused on improving well-being should be provided by nurses. Further studies should be carried out on other factors affecting the well-being of patients as well as pain and pain beliefs on larger samples. (C) 2018 by the American Society for Pain Management Nursin
CYP2A6 gene variants may explain smoking status in a Turkish cohort
No full textOBJECTIVE: Nicotine is the main addictive agent present in tobacco and is principally metabolized by a cytochrome P450-mediated oxidation process. While smoking patterns differ widely among smokers, the metabolization rate of nicotine can also be affected by variations in rates of enzyme activity between individuals. Therefore, we aimed to investigate the significance of CYP2A gene variants in the smoking status in a Turkish population using next-generation sequencing (NGS). METHODS: This case–control study involved 64 subjects with Nicotine dependence (ND) and 36 Non-smoker (NS) subjects. Amplicants designed by “Primer-BLAST” programme were all sequenced using the “Illimuna-MiseqQ-platform”. RESULTS: It was found that there were five SNPs in the CYP2A6 gene (rs8192725, rs7248240, rs1809810, rs8192733 and rs28399435). CYP2A6 rs1809810 homozygous TT genotype and T allele were seen in lower percentages in ND group compared to the NS group (p =0.045; p =0.021). Individuals with CYP2A6 rs1809810 TT genotypes and T allele showed odds ratio of 4.760 and 5.360 for developing protective role ND, respectively. CYP2A6 rs8192733 CC genotype and C allele were both lower in ND group (respectively p =0.001, p =0.023) while GC genotype was higher in the ND group (p =0.004). CYP2A6 rs28399435 TT genotype and T allele were more common in the ND group (respectively p =0.001, p =0.001). CYP2A6 rs28399435 CC genotype was lower in the ND group than in the NS group (p =0.010). CONCLUSIONS:CYP2A6 rs1809810, rs8192733, rs28399435 could be genetic risk factors for ND in a Turkish population. © 2018, © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial
No full textBackground: Omalizumab has demonstrated therapeutic benefits both in controlled clinical trials and real-life studies. However, research concerning the long-term effects and tolerability of omalizumab is needed. The main objective of this study was to evaluate the effectiveness and tolerability of treatment with omalizumab for up to 5 years. Methods: A multicenter, retrospective, chart-based study was carried out to compare documented exacerbations, hospitalizations, systemic steroid requirement, FEV1, and asthma control test (ACT) results during 1 year prior to omalizumab treatment versus at 1, 3, and 5 years of treatment. Adverse events and reasons for discontinuation were also recorded at each time point. Results: Four hundred and sixty-five patients were enrolled in the study. Outcome variables had improved after the 1st year and were sustained after the 3rd and 5th years of treatment with omalizumab. Omalizumab treatment reduced the asthma exacerbation rate by 71.3% (p < 0.001) at 1 year, 64.3% (p < 0.001) at 3 years, and 54.8% (p = 0.002) at 5 years. The hospitalization rate also decreased; by the 5th year of the treatment no patients were hospitalized. ACT results had also improved significantly: 12 (p < 0.001) at 1 year, 12 (p < 0.001) at 3 years, and 12 (p = 0.002) at 5 years. Overall, 12.7% of patients reported adverse events (most of these were mild-to-moderate) and the overall dropout rate was 9.0%. Conclusion: Omalizumab had a significant effect on asthma outcomes and this effect was maintained over 5 years. The drug was found to be generally safe and treatment compliance was good. (C) 2018 S. Karger AG, BaselNovartis Pharmaceuticals Ltd.; NovartisNovartisThe study was sponsored by Novartis Pharmaceuticals Ltd. The sponsor was involved in the design of the study and conducted the analysis according to a detailed analysis agreed by the investigators. The interpretation of the results is that of the author of this paper. Arzu Yorgancioglu, Ferda Oner Erkekol, Dilsad Mungan, Munevver Erdinc, Bilun Gemicioglu, Zeynep Ferhan Ozseker, Papatya Bayrak, Sibel Atis Nayci, Aykut Cilli, Cengiz Kirmaz, Dane Ediger, Arzu Didem Yalcin, Suna Buyukozturk, Sami Ozturk, Rana Isik, Fuat Kalyoncu, and Yavuz Havlucu received grant/research support for consultations, speaking at conferences and for support to attend international conferences from Novartis. Fusun Erdenen, Mustafa Gulec, Ozlem Goksel, Omur Aydin do not have conflict of interest. Idilhan Baloglu Ar, Ahmet Erdogdu work for the Medical Department of Novartis Pharmaceuticals, Istanbul, Turkey
